Reno-protective effect of cilostazole in a rat model of chronic kidney disease

Volume 20 No 10 (2022)

Amira Abd Elazim Kaoud, Ebtsam A Ahmed, Laila A Mahgoub, Dalia M Abd El Motteleb

DOI: 10.48047/NQ.2022.20.10.NQ551161

Abstract

The Chronic kidney disease (CKD) is a common health burden worldwide. Progressive deterioration of kidney function in chronic kidney disease (CKD) is mediated by systemic and renal hypertension, oxidative stress, inflammation, and renal fibrosis. Renin-angiotensin blockade is commonly used to retard CKD progression. Cilostazole (phosphodiestrase III enzyme inhibitor) has been shown to exert antioxidant, antiinflammatory and anti-fibrotic effects. This study was designed to explore the possible protective effects of cilostazol versus valsartan against CKD induced by subtotal 5/6 nephrectomy in rats and to explore the underlying mechanisms. Just after surgery, cilostazole (50 and 100mg/kg/day) and valsartan (30mg/kg/day) were given daily by gavage for 10 weeks.

Keywords

Cilostazole, Valsartan, Chronic kidney disease ,5/6 Nephrectomy

Copyright © Neuroquantology

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Articles published in the Neuroquantology are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJECSE right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.